Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Res. 2013 Sep 26;11(12):10.1158/1541-7786.MCR-13-0237. doi: 10.1158/1541-7786.MCR-13-0237

Figure 3.

Figure 3

None of the compounds used decreased p65 phosphorylation or p-glycoprotein expression (all data normalized to β-actin and vehicle control with S.E.M. shown and doses indicated on the x axis, Figures 3A-3D are the average of 4 independent experiments, Figures 3E and 3F are the average of 6 independent experiments, and a representative Western blot is shown in Figure 3G. Statistical significance is noted by * p<0.05, ** p<0.01, *** p<0.005, and **** p<0.001 relative to vehicle control).